PDS Biotechnology (FRA:EU6) PB Ratio: (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EU6 PDS Biotechnology Corp FRA:EU6
30 GF Score
Price €0.21
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-15), PDS Biotechnology's share price is €0.205. PDS Biotechnology's Book Value per Share for the quarter that ended in Jun. 2026 was €-0.06. Hence, PDS Biotechnology's PB Ratio of today is .

The historical rank and industry rank for PDS Biotechnology's PB Ratio or its related term are showing as below:

FRA:EU6's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.9
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, PDS Biotechnology's average Book Value Per Share Growth Rate was -66.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -51.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -34.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -45.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PDS Biotechnology was -13.00% per year. The lowest was -68.90% per year. And the median was -45.20% per year.

Back to Basics: PB Ratio


PDS Biotechnology  (FRA:EU6) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


PDS Biotechnology PB Ratio Related Terms


PDS Biotechnology PB Ratio Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology PB Ratio Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 8.67 6.31 3.40 4.69

PDS Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.07 4.69 7.74 0.00

FRA:EU6 vs GRCE, HYPD, RNXT: PB Ratio Comparison

For the Biotechnology subindustry, PDS Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's PB Ratio distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's PB Ratio falls into.


FRA:EU6
30GF Score
PDS Biotechnology Corp FRA:EU6
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

PDS Biotechnology's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=0.205/-0.056
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
30GF Score

Get the complete analysis for FRA:EU6

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price